YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
HKEX:1558.HK
8.19 (HKD) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 Q4 | 2023 Q2 | 2022 Q4 | 2022 Q2 | 2021 Q4 | 2021 Q2 | 2020 Q4 | 2020 Q2 | 2019 Q4 | 2019 Q2 | 2018 Q4 | 2018 Q2 | 2017 Q4 | 2017 Q2 | 2016 Q4 | 2016 Q2 | 2015 Q4 | 2015 Q2 | 2014 Q4 | 2014 Q2 | 2013 Q4 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 3,085.583 | 3,209.002 | 2,451.644 | 1,293.308 | 711.542 | 202.246 | 264.408 | 2,083.705 | 3,152.765 | 3,071.259 | 1,028.048 | 1,482.428 | 939.314 | 662.253 | 385.875 | 555.629 | 310.046 | 382.864 | 198.597 | 242.307 | 110.226 |
| Cost of Revenue
| 663.756 | 645.065 | 566.227 | 332.651 | 328.631 | 101.458 | 1.317 | 352.864 | 471.383 | 450.439 | 159.814 | 238.995 | 158.774 | 121.642 | 77.917 | 136.317 | 79.338 | 98.996 | 48.705 | 71.124 | 29.957 |
| Gross Profit
| 2,421.827 | 2,563.937 | 1,885.417 | 960.657 | 382.911 | 100.788 | 263.091 | 1,730.841 | 2,681.382 | 2,620.82 | 868.234 | 1,243.433 | 780.54 | 540.611 | 307.958 | 419.312 | 230.708 | 283.868 | 149.892 | 171.183 | 80.269 |
| Gross Profit Ratio
| 0.785 | 0.799 | 0.769 | 0.743 | 0.538 | 0.498 | 0.995 | 0.831 | 0.85 | 0.853 | 0.845 | 0.839 | 0.831 | 0.816 | 0.798 | 0.755 | 0.744 | 0.741 | 0.755 | 0.706 | 0.728 |
| Reseach & Development Expenses
| 94.023 | 98.264 | 88.708 | 40.906 | 86.987 | 49.666 | 64.445 | 54.983 | 108.876 | 53.743 | 116.575 | 107.528 | 72.875 | 24.04 | 38.378 | 25.858 | 31.118 | 21.185 | 32.708 | 40.876 | 0 |
| General & Administrative Expenses
| 213.595 | 172.107 | 188.78 | 149.672 | 173.278 | 185.124 | 157.746 | 160.322 | 301.364 | 202.049 | 209.895 | 174.49 | 135.611 | 57.374 | 75.572 | 57.139 | 68.404 | 49.835 | 48.167 | 59.693 | 27.578 |
| Selling & Marketing Expenses
| 791.646 | 755.504 | 683.485 | 533.105 | 262.738 | 258.929 | 467.022 | 686.862 | 1,243.846 | 1,117.203 | 320.891 | 332.759 | 254.129 | 117.961 | 70.769 | 110.118 | 36.493 | 40.794 | 41.758 | 18.357 | 15.029 |
| SG&A
| 1,012.144 | 927.335 | 873.613 | 677.434 | 419.772 | 463.473 | 625.548 | 842.013 | 1,556.935 | 1,312.261 | 530.786 | 507.249 | 389.74 | 175.335 | 146.341 | 167.257 | 106.829 | 90.629 | 92.377 | 78.05 | 42.607 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -3.407 | -8.382 | -8.382 |
| Operating Expenses
| 1,494.07 | 1,199.945 | 1,668.525 | 863.22 | 340.613 | 577.809 | 96.995 | 863.908 | 1,493.969 | 1,370.715 | 521.734 | 500.792 | 403.284 | 180.12 | 124.319 | 150.756 | 90.938 | 86.205 | 77.706 | 59.225 | 34.225 |
| Operating Income
| 1,305.716 | 1,484.454 | 79.605 | 243.116 | 37.008 | -495.114 | -75.768 | 909.462 | 1,229.605 | 1,299.91 | 340.794 | 742.641 | 401.989 | 360.491 | 151.01 | 268.556 | 131.756 | 197.663 | 72.191 | 111.958 | 51.361 |
| Operating Income Ratio
| 0.423 | 0.463 | 0.032 | 0.188 | 0.052 | -2.448 | -0.287 | 0.436 | 0.39 | 0.423 | 0.331 | 0.501 | 0.428 | 0.544 | 0.391 | 0.483 | 0.425 | 0.516 | 0.364 | 0.462 | 0.466 |
| Total Other Income Expenses Net
| -440.798 | -222.601 | -3.781 | -279.518 | -115.988 | -93.09 | 328.366 | -151.626 | -133.186 | -127.276 | 14.667 | 4.222 | -12.027 | -2.258 | 37.612 | -4.112 | -0.204 | -14.509 | -6.534 | -14.5 | -10.583 |
| Income Before Tax
| 864.918 | 1,261.853 | 75.824 | -36.402 | -78.98 | -588.204 | 252.598 | 757.836 | 1,096.419 | 1,172.634 | 355.461 | 746.863 | 389.962 | 358.233 | 188.622 | 264.444 | 131.552 | 183.154 | 65.657 | 97.458 | 40.779 |
| Income Before Tax Ratio
| 0.28 | 0.393 | 0.031 | -0.028 | -0.111 | -2.908 | 0.955 | 0.364 | 0.348 | 0.382 | 0.346 | 0.504 | 0.415 | 0.541 | 0.489 | 0.476 | 0.424 | 0.478 | 0.331 | 0.402 | 0.37 |
| Income Tax Expense
| 33.016 | 237.929 | 5.877 | 3.94 | 1.767 | 81.227 | 31.928 | 141.095 | 149.404 | 212.464 | 65.034 | 136.072 | 58.877 | 62.961 | 23.01 | 49.459 | 19.05 | 29.906 | 12.371 | 15.401 | 6.943 |
| Net Income
| 963.129 | 1,029.495 | 109.401 | -32.798 | -80.621 | -507.028 | 221.947 | 617.508 | 950.285 | 968.424 | 307.992 | 634.544 | 345.241 | 301.86 | 165.612 | 214.985 | 112.502 | 153.248 | 53.286 | 82.057 | 33.836 |
| Net Income Ratio
| 0.312 | 0.321 | 0.045 | -0.025 | -0.113 | -2.507 | 0.839 | 0.296 | 0.301 | 0.315 | 0.3 | 0.428 | 0.368 | 0.456 | 0.429 | 0.387 | 0.363 | 0.4 | 0.268 | 0.339 | 0.307 |
| EPS
| 1.09 | 1.17 | 0.12 | -0.04 | -0.092 | -0.58 | 0.096 | 0.63 | 0.99 | 1.09 | 0.34 | 0.7 | 0.38 | 0.33 | 0.18 | 0.24 | 0.16 | 0.25 | 0.079 | 0.091 | 0.038 |
| EPS Diluted
| 1.09 | 1.17 | 0.12 | -0.037 | -0.092 | -0.58 | 0.2 | 0.56 | 0.84 | 1.09 | 0.34 | 0.7 | 0.38 | 0.33 | 0.18 | 0.24 | 0.16 | 0.25 | 0.079 | 0.091 | 0.038 |
| EBITDA
| 1,499.41 | 1,673.063 | 274.302 | 417.181 | 173.372 | -379.926 | -8.581 | 958.816 | 1,268.178 | 1,343.17 | 374.593 | 769.93 | 428.955 | 377.32 | 165.245 | 281.77 | 144.707 | 210.459 | 87.125 | 128.969 | 59.348 |
| EBITDA Ratio
| 0.486 | 0.521 | 0.112 | 0.323 | 0.244 | -1.879 | -0.032 | 0.46 | 0.402 | 0.437 | 0.364 | 0.519 | 0.457 | 0.57 | 0.428 | 0.507 | 0.467 | 0.55 | 0.439 | 0.532 | 0.538 |